Abstract
Final draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended nirmatrelvir plus ritonavir (Paxlovid; Pfizer), tocilizumab (RoActemra; Roche) and sotrovimab (Xevudy; GlaxoSmithKline) as options for treating COVID-19 in adults. This advice contrasts with previous draft guidance, published on 16 November 2022, in which NICE recommended the use of baricitinib […]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
